Effect of bortezomib combined with doxorubicin on lymphoblastic lymphoma Molt-4 cells
10.3760/cma.j.issn.1009-9921.2013.03.002
- VernacularTitle:硼替佐米联合多柔比星对淋巴母细胞淋巴瘤Molt-4细胞的作用
- Author:
Wei ZHAO
;
Ping YANG
;
Jing WANG
;
Hongmei JING
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Lymphoma,lymphoblastic;
Molt-4 cells;
Bortezomib;
Doxorubicin
- From:
Journal of Leukemia & Lymphoma
2013;22(3):132-135
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of bortezomib combined with doxorubicin on lymphoblastic lymphoma cell line Molt-4.Methods Molt-4 cells were cultured in the presence of bortezomib and doxorubicin,cell viability was monitored by CCK-8 and trypan-blue exclusion.Apoptosis was detected by flow cytometry and mitochondrial membrane potential,expression of Fas was also measured with flow cytometry.Results Molt-4 cell proliferation was substantially inhibited in concentration-dependent manners when treated with either bortezomib or doxorubicin.The combination of both drugs synergistically inhibited Molt-4 cell proliferation at 48 hours [(57.24±0.10) ％].Combination therapy further enhanced bortezomib and doxorubicin induced apoptosis [48 h (23.08±1.25) ％] (P ＜ 0.05).Detection of mitochondrial membrane potential showed that combination therapy could promote apoptosis (15.84 ％,5.38 ％,5.52 ％) but did not significantly change the level of Fas expression (P ＞ 0.05).Conclusion Combination therapy of bortezomib with doxorubicin efficiently inhibits proliferation and induces apoptosis of Molt-4 cells.Activation of mitochondrial and intrinsic apoptotic pathway may play important roles.
